LENEXA, Kansas — Cleveland Clinic cardiologist Dr. James Young has joined the board of cardiovascular drugmaker VasoGenix Pharmaceuticals.
VasoGenix has worked with the Clinic since 2005, when the health system agreed to design and conduct (pdf) a Phase I/II trial for the company’s main drug: a peptide-based heart-failure treatment distributed through neural tissue that works in several ways to prevent a myocardial infarction.
Young is chairman of the Clinic’s Division of Medicine and focuses on heart transplant and heart failure.
“The company’s vision to enhance the quality of life of heart failure patients while impacting the cost of treatment by reducing hospitalization time and rates of readmission is consistent with the critical needs we have in heart failure now and in the future,” Young stated in a press release.
Young is VasoGenix’s third new board member in the last four months. In March it named pharmaceutical executive Judith Hemberger to its board, and in February it added former Avax Technologies Chief Executive Richard P. Rainey.
No comments:
Post a Comment